NCT03344328View on ClinicalTrials.gov

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

January 31, 2020

Conditions
Chemotherapy Induced Peripheral NeuropathyMultiple Myeloma
Interventions
DRUG

Bortezomib

The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.

Trial Locations (1)

63003

CHU Clermont-Ferrand, Clermont-Ferrand

All Listed Sponsors
lead

University Hospital, Clermont-Ferrand

OTHER

NCT03344328 - Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders. | Biotech Hunter | Biotech Hunter